Psychopharmacology
June 1, 2022
Pablo Mallaroni, Natasha L. Mason, F R J Vinckenbosch et al.
16 citations
Novel psychedelics (NPs) are an expanding set of compounds, presenting new challenges for drug policy and opportunities for clinical research. Unlike their classical derivatives, little is known regarding their use profiles or their subjective effects. The purpose of this study was to compile usage patterns and adverse event rates for individual NPs belonging to each of three main psychedelic...
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology
November 1, 2020
Natasha L. Mason, K P C Kuypers, F Müller et al.
261 citations
There is growing interest in the therapeutic utility of psychedelic substances, like psilocybin, for disorders characterized by distortions of the self-experience, like depression. Accumulating preclinical evidence emphasizes the role of the glutamate system in the acute action of the drug on brain and behavior; however this has never been tested in humans. Following a double-blind,...
Journal of psychopharmacology (Oxford, England)
May 2009
J G Ramaekers, G Kauert, E L Theunissen et al.
Performance impairment during Delta(9)-tetrahydrocannabinol (THC) intoxication has been well described in occasional cannabis users. It is less clear whether tolerance develops to the impairing effects of THC in heavy users of cannabis. The aim of the present study was to assess neurocognitive performance during acute THC intoxication in occasional and heavy users. Twenty-four subjects (12...
Psychopharmacology
May 2005
M Rizzo, C T J Lamers, C G Sauer et al.
Illicit drug use can increase driver crash risk due to loss of control over vehicle trajectory. This study asks, does recreational use of +/-3,4-Methylenedioxymethamphetamine (MDMA; ecstasy) and tetrahydrocannabinol (THC; marijuana) impair cognitive processes that help direct our safe movement through the world? This study assesses the residual effects of combined MDMA/THC use, and of THC use...